GAIASO Theranostics, an Australia-based biotech company pioneering next-generation precision radiopharmaceuticals for women’s cancers, has appointed Dr. Tracey Brown as its new Chief Executive Officer (CEO).  

Dr. Brown brings extensive international experience across oncology and radiopharmaceutical development, having held senior leadership roles at Telix Pharmaceuticals, Anatara Lifesciences and Alchemia.

Earlier in her career, she co-founded Meditech Research, inventing the pioneering HyACT oncology drug-delivery platform and building a substantial patent estate while leading the portfolio strategy. She began her career at Monash University, where she led the Hyaluronan Laboratory and held research and adjunct appointments. Dr Brown holds a PhD in Biochemistry and Molecular Biology from Monash University and is a Graduate of the Australian Institute of Company Directors.

“I lost my mum to ovarian cancer and ever since, I’ve focused my career on translating science into real options for women and cancer patients. I’m now thrilled to lead GAIASO Theranostics, because our technology has the potential to make a real difference for patients and their families. I’m here to make sure brilliant science becomes accessible care,” Dr. Brown said.

GAIASO’s Chief Medical Officer, Professor Rod Hicks, welcomed her appointment, “Her outstanding track record in leading complex global clinical programmes, combined with her pioneering work in oncology drug development, makes her uniquely placed to guide our company into its next phase. Tracey’s vision and passion for improving patient outcomes perfectly align with GAIASO’s mission to redefine cancer care.”

As CEO, Dr. Brown will oversee strategy, science, product development, partnerships, capital planning, and governance, while Professor Hicks continues to lead scientific development across GAIASO’s programmes. The company is also finalising its Board and Management Team under the leadership of Chairperson Professor Hon Jill Hennessy.

Headquartered in North Melbourne, Victoria, GAIASO Theranostics designs and develops next-generation theranostic products, combining cutting-edge technology with molecular and clinical expertise to rapidly advance new solutions for women with cancer.

The company is building on key collaborations and partnerships with PreMIT (Australia), Navigo Proteins (Germany), MTIC (Australia), and several other partners yet to be announced.